ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-FGFR3 Antibody-drug Conjugate BHV-1530

Its studies are led by Biohaven Therapeutics.

Furthest: phase 1, since Mar 4, 20251 company-led study, 1 open or runningNext primary completion: Mar 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biohaven Therapeutics11 open or runningphase 1since Mar 4, 2025Mar 4, 2025Mar 2029phase 1 · NCT06874335

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2025First study: phase 1 study in Solid TumorFirst studyNCT06874335 · 140 planned · United States

Ahead

  1. Mar 2029Primary completion: phase 1 study in Solid TumorNCT06874335

TargetBeta

FGFR3 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against human fibroblast growth factor receptor type 3 (FGFR3) ”NCIt, by rule

Other programs on FGFR3

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
masitinibruleAB Sciencephase 338
infigratinibruleBridgeBiophase 317
pemigatinibruleIncytephase 316
futibatinibruleOtsukaphase 310
vepugratinibruleEli Lillyphase 35
dabogratinibruletyra-biosciences-incphase 25
FGFR3/4 Inhibitor TYRA-430ruletyra-biosciences-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06874335Solid Tumor · United States1RecruitingMar 2029140

How it is read

Names in the registry

  • “BHV-1530”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.